Executive Summary
Sagittarius Life Science Corporation operates as a biotechnology research company. More Details
Risk Analysis
Snowflake Analysis
Mediocre balance sheet and overvalued.
Share Price & News
How has Sagittarius Life Science's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: 3205 is less volatile than 75% of TW stocks over the past 3 months, typically moving +/- 2% a week.
Volatility Over Time: 3205's weekly volatility (2%) has been stable over the past year.
Market Performance
7 Day Return
1.0%
3205
-0.8%
TW Personal Products
-0.2%
TW Market
1 Year Return
-30.0%
3205
-14.0%
TW Personal Products
33.6%
TW Market
Return vs Industry: 3205 underperformed the TW Personal Products industry which returned -14% over the past year.
Return vs Market: 3205 underperformed the TW Market which returned 33.6% over the past year.
Shareholder returns
| 3205 | Industry | Market | |
|---|---|---|---|
| 7 Day | 1.0% | -0.8% | -0.2% |
| 30 Day | -3.1% | -1.8% | 3.7% |
| 90 Day | -7.1% | -3.6% | -0.2% |
| 1 Year | -30.0%-30.0% | -11.5%-14.0% | 37.5%33.6% |
| 3 Year | -50.6%-50.6% | -2.6%-11.4% | 77.4%59.1% |
| 5 Year | -81.0%-82.5% | 15.7%0.3% | 121.9%84.7% |
Long-Term Price Volatility Vs. Market
How volatile is Sagittarius Life Science's share price compared to the market and industry in the last 5 years?
Simply Wall St News
5 months ago | Simply Wall St
We Think Sagittarius Life Science (GTSM:3205) Can Afford To Drive Business GrowthValuation
Is Sagittarius Life Science undervalued compared to its fair value and its price relative to the market?
1.56x
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate 3205's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate 3205's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: 3205 is unprofitable, so we can't compare its PE Ratio to the TW Personal Products industry average.
PE vs Market: 3205 is unprofitable, so we can't compare its PE Ratio to the TW market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate 3205's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: 3205 is good value based on its PB Ratio (1.6x) compared to the TW Personal Products industry average (2x).
Future Growth
How is Sagittarius Life Science forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
17.8%
Forecasted Household industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Sagittarius Life Science has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Past Performance
How has Sagittarius Life Science performed over the past 5 years?
-57.9%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 3205 is currently unprofitable.
Growing Profit Margin: 3205 is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: 3205 is unprofitable, and losses have increased over the past 5 years at a rate of 57.9% per year.
Accelerating Growth: Unable to compare 3205's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 3205 is unprofitable, making it difficult to compare its past year earnings growth to the Personal Products industry (17.9%).
Return on Equity
High ROE: 3205 has a negative Return on Equity (-14.65%), as it is currently unprofitable.
Financial Health
How is Sagittarius Life Science's financial position?
Financial Position Analysis
Short Term Liabilities: 3205's short term assets (NT$484.2M) exceed its short term liabilities (NT$129.5M).
Long Term Liabilities: 3205's short term assets (NT$484.2M) exceed its long term liabilities (NT$21.3M).
Debt to Equity History and Analysis
Debt Level: 3205's debt to equity ratio (3.6%) is considered satisfactory.
Reducing Debt: 3205's debt to equity ratio has increased from 1.9% to 3.6% over the past 5 years.
Debt Coverage: 3205's operating cash flow is negative, therefore debt is not well covered.
Interest Coverage: Insufficient data to determine if 3205's interest payments on its debt are well covered by EBIT.
Balance Sheet
Dividend
What is Sagittarius Life Science current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate 3205's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate 3205's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if 3205's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if 3205's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: 3205 is not paying a notable dividend for the TW market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of 3205's dividend in 3 years as they are not forecast to pay a notable one for the TW market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
CEO
Sagittarius Life Science has no CEO, or we have no data on them.
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
Sagittarius Life Science Corp's company bio, employee growth, exchange listings and data sources
Key Information
- Name: Sagittarius Life Science Corp
- Ticker: 3205
- Exchange: TPEX
- Founded: 1987
- Industry: Personal Products
- Sector: Household
- Market Cap: NT$849.440m
- Shares outstanding: 32.55m
- Website: https://www.naturalbiokey.com
Number of Employees
Location
- Sagittarius Life Science Corp
- No.3, Yuanqu Street
- 10F-6
- Taipei
- 115
- Taiwan
Listings
Biography
Sagittarius Life Science Corporation operates as a biotechnology research company. It engages in the development of Chinese herbal medicine technology platform for the treatment of various diseases. The co...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2021/09/17 15:38 |
| End of Day Share Price | 2021/09/17 00:00 |
| Earnings | 2021/06/30 |
| Annual Earnings | 2020/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.